Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on April 5, 2019. The Company is a Delaware corporation and an emerging growth company. The report details the entry into a material definitive agreement and updates on regulatory progress for its lead product candidate.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial disclosure relates to a new capital raising mechanism:
- Offering Size: Up to $50,000,000 in aggregate offering price.
- Instrument: Common stock, $0.0001 par value per share.
- Agent: Jefferies LLC.
- Commission: 3.0% of gross proceeds from sales.
- Method: "At the market" offering on The Nasdaq Global Market.
Material Changes
The Company entered into an Open Market Sale Agreement with Jefferies LLC, enabling the sale of shares from time to time. This agreement is filed under an existing shelf Registration Statement on Form S-3 that became effective on February 12, 2019. No other material financial changes or operational shifts are detailed in this specific report.
Guidance, Outlook, and Regulatory Status
While no financial guidance is provided, the Company reported significant regulatory progress regarding its product DEXTENZA:
- Regulatory Action: The FDA accepted the Company's sNDA (supplemental New Drug Application) for DEXTENZA for the treatment of post-surgical ocular inflammation on March 28, 2019.
- Target Action Date: The FDA has set a target decision date of November 10, 2019.
- Contingencies: The offering of shares is subject to the terms of the Sales Agreement and applicable securities laws. The Company or Jefferies may suspend or terminate the offering upon notice.
Investor Verification Checklist
- Verify the current cash position and burn rate to assess the necessity of the $50 million equity offering.
- Monitor the FDA decision timeline for DEXTENZA, with a target action date of November 10, 2019.
- Review the prospectus supplement filed under the S-3 Registration Statement (File No. 333-229085) for detailed terms of the offering.
- Track the volume of shares sold under the "at the market" agreement to gauge potential dilution.